The group of medications known as GLP-1, including exenatide, Lixisenatide, Liraglutide, Albiglutide, Dulaglutide, and Semaglutide, have emerged as effective therapeutic options for both conditions for the management of Type 2 diabetes mellitus (T2DM) and obesity (Wilding et al., 2021; Alfaris et al., 2024). The gene discussed is GLP1R; the disease is obesity disorder.